Results 221 to 230 of about 6,225,903 (287)

ORIGINALES : La obra científica de J. Albarrán 1885 a 1912 [PDF]

, 1960
Puigvert Gorro, Antoni
core  

NAD+‐Dependent Enzyme SIRT3 Limits Intestinal Epithelial Cell Functions Through NAD+ Synthesis Pathway in Colorectal Cancer

Advanced Science, EarlyView.
Microbiota‐derived quinolinic acid is used as an alternative source of replenishing the intracellular NAD+ pool induced by SIRT3 deficiency to regulate intestinal epithelial cell and T cell function, which has implications for targeting intestinal epithelial cells as an approach to the treatment of immune‐associated diseases, including colorectal ...
Ruiying Niu, Yingjie Dong, Jianghui Tong, Jingxuan Xia, Longhao Zhao, Zi Geng, Yingxin Lin, Jinghe Zhang, Xinyi Liu, Manqi Fang, Xi Jin, Yujing Bi, Guangwei Liu   +12 more
wiley   +1 more source

Multiple primary cancers with prostate malignant tumor as the initial diagnosis: a case report. [PDF]

Discov Oncol
Yang K, Zhou J.
europepmc   +1 more source

Hipercalcemia asociada a linfoma como causa de insuficiencia renal [PDF]

, 2001
Aceña Fabián, M. Carmen, García-Belenguer, Sylvia, Pérez, Montserrat, Unzueta, Amaia   +3 more
core  

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Correction to "Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers". [PDF]

CA Cancer J Clin
europepmc   +1 more source

The Role of DNA Methyltransferases in Urinary System Diseases. [PDF]

Cancer Innov
Dong W, Pei S, Zhu D, Zeng C, Qiu Y, Wu Y, Jia X, Zhang S, Li C, Zhang W, Zhang W, Chen Z.   +11 more
europepmc   +1 more source

Dipiperazine‐Phenyl Derivatives Based on Convergent Molecular Platforms Can Reverse Multidrug Resistance in Gram‐Negative Bacteria by Inhibiting Efflux and Permeabilizing Cell Membranes

Advanced Science, EarlyView.
By integrating a convergent molecular platform strategy, this study designed a novel dual‐target C5 to combat multidrug‐resistant Gram‐negative bacteria. C5 synergistically enhances antibiotic efficacy by inhibiting efflux pumps and increasing bacterial membrane permeability.
Jiale Dong, Ting Guo, Yi Huang, Yangchun Ma, Weijin Chen, Jie Xue, Jun Jiang, Enhui Dong, Yue Kong, Hang Ding, Wenlong Zhang, Shutao Ma   +11 more
wiley   +1 more source

Targeting SMPDL3B to Ameliorate Radiation- and Cisplatin-Induced Renal Toxicity. [PDF]

Cells
Ahmad A, Mallela SK, Ansari S, Alnukhali M, Merscher S, Mitrofanova A, Zeidan YH, Pollack A, Fornoni A, Marples B.   +9 more
europepmc   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source